Hemodynamic and Cardiac Effects of BMS-180448, a Novel K+ATP Opener, in Anesthetized Dogs and Isolated Rat Hearts

Pharmacology

Volumn 52, Issue 2, 1996, Pages 101-112

  D’alonzo, Albert J ^a   Grover, Gary J ^a   Darbenzio, Raymond B ^a   Sewter, Joseph C ^a   Hess, Thomas A ^a   Dzwonczyk, Steven ^a   Sleph, Paul G ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Canine; Cromakalim; Flow; Pressure; Systemic resistance; Vascular resistance

Indexed keywords

CROMAKALIM; N (4 CHLOROPHENYL) N' CYANO N'' (6 CYANO 3,4 DIHYDRO 3 HYDROXY 2,2 DIMETHYL 2H 1 BENZOPYRAN 4 YL)GUANIDINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DOG; DRUG POTENCY; HEART LEFT VENTRICLE PRESSURE; HEART PROTECTION; HEART RATE; INDUCED HYPOTENSION; ISOLATED HEART; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR RESISTANCE; VASODILATATION;

EID: 0030047986     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139373     Document Type: Article

References (26)

1. Erne P. Hermsmcycr K: Modulation of intracellular calcium by potassium channel openers in vascular muscle. Naunyn Schmiedeberg’s Arch Pharmacol 1991:344:706-715.
2. Hamilton TC. Weir SW. Weston AH: Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol 1986: 88:103-111.
3. 2+ of contractile elements in canine coronary artery. Naunyn Schmicdcberg's Arch Pharmacol 1993:347:438-444.
4. + efflux and spontaneous activity in guinea-pig portal vein. Br J Pharmacol 1987;91:569-578.
5. dcLaCoussavc JE. Eldedjam J-J. Bruelle P. et al: Electrophysiologic and arrhythmogenic effects of the potassium channel agonist BRL 38227 in anesthetized dogs. J Car-diovasc Pharmacol 1993,22:722-730.
6. Longman SD. Clapman JC, Wilson C. et al: Cromakalim, a potassium channel activator: A comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil. J Cardiovasc Pharmacol 1988:12: 535-542.
7. Shen Y-T. Vatner SF: Effects of a K'ATP channel opener, lemakalim. on systemic, coronary and regional vascular dynamics in conscious dogs: Comparison with nifedipine, adenosine, nitroglycerin and acetylcholine. J Pharmacol Exp Ther 1993;265:1026-1037.
8. Cole WC: ATP-sensitive K+ channels in cardiac ischemia: An endogenous mechanism for protection of the heart. Cardiovasc Drugs Ther 1993:7:527-537.
9. Grover GJ: Protective effects of ATP sensitive potassium channel openers in models of myocardial ischaemia. Cardiovasc Res 1994:28: 778-782.
10. Opie LH: Modulation of ischemia by regulation of the ATP-scnsitive potassium channel. Cardiovasc Drugs Ther 1993;7:507-513
11. + channel opener RP 52891 reduced experimental infarct size in dogs in the absence of systemic hemodynamic changes. J Pharmacol Exp Ther 1991:259:961-967.
12. Cole WC, McPherson CD, Sontag D: ATP-regulated channels protect the myocardium against ischemic/ reperfusion damage. Circ Res 1991; 69:571-581.
13. D’Alonzo AJ. Darbenzio RB. Parham CS. et al: Effects of intracoronary cromakalim on postischemic contractile function and monophas-ic action potential duration: Possible mechanism of action and ischemia selectivity. Cardiovasc Res 1992;26:1046-1053.
14. Grover GJ. McCullough JR. Henry DE. et al: Antiischemic effects of the potassium channel activators pina-cidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. J Pharmacol Exp Titer 1989:251:98-104.
15. Grover GJ. Sargent CA. McCullough JR. el al: Discovery of a car-dioselcctive ATP-sensitive potassium channel opener: BMS-180448. J Cardiovasc Pharmacol 1995;25: 40-50.
16. Grover GJ. Parham CS: Protective effects of the cardiosclcctivc ATP-sensitive potassium channel opener BMS-180448 in two stunned myocardial models. J Am Coll Cardiol I994:23:42A.
17. Katz LB, Giardino EC. Salata JJ, el al: RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: A potential antihypertensive and antianginal agent. J Pharmacol ExpTher 1993:267:648-656.
18. Shoji T. Aki Y. Fukui K, et al: Effects of cromakalim, a potassium channel opener, on regional blood flow in conscious spontaneously hypertensive rats. Eur J Pharmacol 1990:186:119-123.
19. Gotanda K, Yokoyama H. Satoh K. et al: Cardiohemodynamic effects of cromakalim and pinacidil. potassium-channel openers, in the dog, special reference to venous return. Cardiovasc Drugs Ther 1989;3:507-515.
20. Grover G. Slcph P. Dzwonczyk S: Pharmacologic profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthetized dogs. J Cardiovasc Pharmacol 1990;16:853-864.
21. + channel openers on opiate analgesia, in rats. Pharmacol Res 1992;25(suppl2):268.
22. D'Alonzo AJ. Hess TA, Darbcnzio RB. et al: Effects of cromakalim or pinacidil on pacing- and ischemia-induced ventricular fibrillation in the anesthetized pig. Basic Res Cardiol 1994;89:163-176.
23. Honerjager P: Regulation of myocardial force of contraction by sarco-lemmal ion channels, the sodium pump, and the sodium-calcium exchanger: in Rupp H (cd): Regulation of Heart Function: Basic Concepts and Clinical Applications. New York. Thicme, 1986, pp 159-177.
24. Donnelly R, Elliott HL, Meredith PA. et al: Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects. J Cardiovasc Pharmacol 1990:16:791-795.
25. Fox JS. Whitehead EM. Shanks RG: Cardiovascular effects of cromakalim (BRL 34915) in healthy volunteers. Br J Clin Pharmacol 1991:32: 45-49.
26. Goldberg MR: Clinical pharmacology of pinacidil. a prototype for drugs that affect potassium channels. J Cardiovasc Pharmacol 1988; 12: S41-47.